Sujin (Mary) Jung has served as Director of Clinical Research, and currently as Director of Clinical Affairs since 2014. In her role, she leads and coordinates a broad range of activities across clinical trials, national cardiovascular device development projects, and regulatory compliance.

​

Mary brings extensive hands-on experience in the execution of clinical studies, along with a strong command of intellectual property management and quality assurance in accordance with Korean Good Manufacturing Practice (KGMP) standards under the Ministry of Food and Drug Safety (KFDA).

​

Her multidisciplinary expertise ensures that Tau’s clinical operations meet the highest standards of regulatory rigor, scientific integrity, and patient-centered outcomes. She has a Master’s degree in Biomaterials Engineering.

​

​